These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 28532400)

  • 1. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
    BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases.
    Fanetti G; Marvaso G; Ciardo D; Rese A; Ricotti R; Rondi E; Comi S; Cattani F; Zerini D; Fodor C; de Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 Apr; 35(5):75. PubMed ID: 29671075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
    Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
    Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
    Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
    Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer.
    Chaw CL; deSouza NM; Khoo V; Suh YE; van As N
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):509-517. PubMed ID: 32423621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
    Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
    Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
    Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
    PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
    Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
    [No Abstract]   [Full Text] [Related]  

  • 12. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
    Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
    Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival in patients with
    Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
    Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
    Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes.
    Jereczek-Fossa BA; Fanetti G; Fodor C; Ciardo D; Santoro L; Francia CM; Muto M; Surgo A; Zerini D; Marvaso G; Timon G; Romanelli P; Rondi E; Comi S; Cattani F; Golino F; Mazza S; Matei DV; Ferro M; Musi G; Nolè F; de Cobelli O; Ost P; Orecchia R
    Clin Genitourin Cancer; 2017 Aug; 15(4):e623-e632. PubMed ID: 28185875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Zhang B; Leech M
    Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stereotactic body radiotherapy (SBRT) for the treatment of bone metastases in oligometastasised prostate cancer].
    Sage EK; Vogel MME; Dewes S; Devecka M; Eiber M; Gschwend JE; Combs SE; Schiller K
    Aktuelle Urol; 2020 Jun; 51(3):265-270. PubMed ID: 32268437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
    Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
    Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
    Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
    World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
    Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.